应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
LNAI Lunai Bioworks
休市中 11-20 16:00:00 EST 延时
资讯
新帖
简况
Lunai Bioworks获Tanaist帕金森氏症细胞表型分析技术独家授权
美股速递 · 09-22
Lunai Bioworks获Tanaist帕金森氏症细胞表型分析技术独家授权
Lunai Bioworks面临二次修订诉状:指控证券欺诈与市场操纵,涉Rule 10B-5
美股速递 · 08-27
Lunai Bioworks面临二次修订诉状:指控证券欺诈与市场操纵,涉Rule 10B-5
Lunai Bioworks (Nasdaq: Lnai)与Brainstorm Therapeutics签署最终合作协议,帕金森病初步数据读出瞄准2027年上半年
美股速递 · 08-05
Lunai Bioworks (Nasdaq: Lnai)与Brainstorm Therapeutics签署最终合作协议,帕金森病初步数据读出瞄准2027年上半年
联邦法官批准Lunai Bioworks加速取证程序,以识别“裸卖空”交易者
美股速递 · 05-22
联邦法官批准Lunai Bioworks加速取证程序,以识别“裸卖空”交易者
Lunai Bioworks宣布1比8反向拆股,5月22日生效以维持纳斯达克上市地位
环球市场播报 · 05-21
Lunai Bioworks宣布1比8反向拆股,5月22日生效以维持纳斯达克上市地位
Lunai Bioworks完成2000万美元优先股发行,收购中枢神经递送与神经治疗知识产权
美股速递 · 05-04
Lunai Bioworks完成2000万美元优先股发行,收购中枢神经递送与神经治疗知识产权
加载更多
公司概况
公司名称:
Lunai Bioworks
所属市场:
PINK
上市日期:
--
主营业务:
Lunai Bioworks Inc.于2011年1月18日在特拉华州注册成立。Lunai Bioworks Inc.是一家人工智能驱动的生物技术公司,专注于精准医疗、生物标志物发现以及针对中枢神经系统(CNS)疾病、生物防御和其他严重疾病的疗法开发。公司主要通过两家子公司开展业务:Renovaro Biosciences(负责细胞和基因治疗项目)以及 BioSymetrics(于2025年4月8日收购,提供用于生物标志物发现和疗法开发的人工智能与机器学习平台,涵盖癌症诊断、中枢神经系统疾病和生物防御等多个领域)。第三家全资子公司Lunai Bioworks IP, Inc.持有源自 2026 年 5 月收购Neurobridge交易的知识产权,其中包括N2B鼻内药物递送平台。尽管GEDi Cube B.V.在截至2025年9月30日的季度内经历了破产及合并报表范围剔除,但公司的战略方向保持不变;BioSymetrics拥有的互补性能力确保了公司人工智能驱动的生物医学研发战略得以延续并拓展。目前的合并业务涵盖Renovaro Biosciences的细胞与基因治疗项目以及BioSymetrics的人工智能驱动生物技术平台,通过结合多模态数据分析与实验生物学,旨在加速研发进程,并提升疗法及化学防御制剂发现的效率。
发行价格:
--
{"stockData":{"symbol":"LNAI","market":"US","secType":"STK","nameCN":"Lunai Bioworks","latestPrice":0.1648,"timestamp":1795208400000,"preClose":0.1648,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":3731541,"shares":5034500,"eps":-1.059999,"marketStatus":"休市中","change":0,"latestTime":"11-20 16:00:00 EST 延时","open":0.1648,"high":0.1648,"low":0.1648,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.059999,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1795424400000},"marketStatusCode":7,"adr":0,"listingDate":1793332800000,"exchange":"PINK","adjPreClose":0.1648,"volumeRatio":0},"requestUrl":"/m/hq/s/LNAI/","defaultTab":"news","newsList":[{"id":"1187752091","title":"Lunai Bioworks获Tanaist帕金森氏症细胞表型分析技术独家授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1187752091","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187752091?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:21","pubTimestamp":1790083271,"startTime":"0","endTime":"0","summary":"Lunai Bioworks宣布了一项重大突破——该公司已成功取得Tanaist开发的细胞表型分析技术在帕金森氏症领域的独家使用权。这一协议的达成,标志着Lunai Bioworks在神经退行性疾病研究领域迈出了关键性的一步。通过这项技术的加持,Lunai Bioworks将得以更深入地探索帕金森氏症的病理机制,从而加速相关治疗方案的研发进程。Lunai Bioworks方面表示,获得该技术的独家权利后,公司将整合内部资源,全力推进技术转化与临床应用研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141288662","title":"Lunai Bioworks面临二次修订诉状:指控证券欺诈与市场操纵,涉Rule 10B-5","url":"https://stock-news.laohu8.com/highlight/detail?id=1141288662","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141288662?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:29","pubTimestamp":1787837353,"startTime":"0","endTime":"0","summary":"Lunai Bioworks——这家生物科技公司如今站在了风口浪尖。一份二次修订的诉状正式提交,直指其涉嫌证券欺诈和市场操纵行为,矛头对准了Rule 10B-5下的法律责任。Rule 10B-5,这条美国证券法中的核心条款,如今成了悬在Lunai Bioworks头顶的达摩克利斯之剑。而Lunai Bioworks方面,则面临着日益紧迫的辩护压力。截至目前,Lunai Bioworks尚未就诉状内容发表正式声明。这场围绕证券欺诈与市场操纵的较量,不仅关乎一家公司的命运,更折射出资本市场中规则与行为的永恒博弈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141563687","title":"Lunai Bioworks (Nasdaq: Lnai)与Brainstorm Therapeutics签署最终合作协议,帕金森病初步数据读出瞄准2027年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1141563687","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141563687?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:30","pubTimestamp":1785871809,"startTime":"0","endTime":"0","summary":"Lunai Bioworks(纳斯达克代码:Lnai)已与Brainstorm Therapeutics达成最终合作协议,这一合作明确聚焦于帕金森病领域。双方共同将首个关键数据读出节点设定在2027年上半年。这项协议标志着两家公司在神经退行性疾病治疗方面迈出了实质性的一步,旨在通过资源整合加速研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145485751","title":"联邦法官批准Lunai Bioworks加速取证程序,以识别“裸卖空”交易者","url":"https://stock-news.laohu8.com/highlight/detail?id=1145485751","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145485751?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:17","pubTimestamp":1779455837,"startTime":"0","endTime":"0","summary":"联邦法院近日作出裁决,批准了Lunai Bioworks公司提出的加速取证请求。这一决定将使该公司能够迅速获取相关交易记录,旨在查明并确认涉嫌对其股票进行“裸卖空”操作的交易者身份。\n所谓“裸卖空”,是指卖方在未实际借入股票的情况下直接进行卖空交易,这种行为在多数市场受到严格监管甚至禁止。Lunai Bioworks此次获得法院支持的取证程序,标志着其在应对潜在市场操纵行为方面取得了关键进展。通过加速发现程序,公司有望更快地收集证据,厘清交易活动中的异常模式。\n这一法律行动反映出上市公司日益关注并积极应对可能影响股价的市场交易行为。随着取证程序的推进,后续进展或将引起市场参与者的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637272438","title":"Lunai Bioworks宣布1比8反向拆股,5月22日生效以维持纳斯达克上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2637272438","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637272438?lang=zh_cn&edition=full","pubTime":"2026-05-21 03:05","pubTimestamp":1779303900,"startTime":"0","endTime":"0","summary":"AI驱动的生命科学公司Lunai Bioworks周三宣布,将对其普通股实施1比8的反向股票分割。该拆股将于美国东部时间2026年5月22日凌晨12:01正式生效,当日纳斯达克开盘后将以拆股调整后的价格进行交易,股票代码仍为“LNAI”,但将启用新的CUSIP编号。 为改善基本面并创造新收入来源,Lunai Bioworks近期实施了一系列战略举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-21/doc-inhyquqa6091712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONEQ","QLD","07261","QMAR","PSQ","QDTE","QQQE","QQQJ","TECS","IYW","07522","SQQQ","QQQM","BK4139","QDEC","GPIQ","NVIW.SI","LNAI","BK4007","02834","NJUL","NAPR","FTEC","QYLG","QQQX","QID","JEPQ","BK1147","QQQA","07568","03034","07266","TQQY","TQQQ","NJAN","03455","09086","MNQmain","QQQ","QQQY","09834","NOCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111041885","title":"Lunai Bioworks完成2000万美元优先股发行,收购中枢神经递送与神经治疗知识产权","url":"https://stock-news.laohu8.com/highlight/detail?id=1111041885","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111041885?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:35","pubTimestamp":1777901711,"startTime":"0","endTime":"0","summary":"Lunai Bioworks已成功完成一笔价值2000万美元的优先股发行。此次融资的核心目的在于收购中枢神经递送及神经治疗领域的相关知识产权组合。这一战略性举措标志着该公司在强化其神经科学平台方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovarogroup.com;www.lunaibioworks.com","description":"Lunai Bioworks Inc.于2011年1月18日在特拉华州注册成立。Lunai Bioworks Inc.是一家人工智能驱动的生物技术公司,专注于精准医疗、生物标志物发现以及针对中枢神经系统(CNS)疾病、生物防御和其他严重疾病的疗法开发。公司主要通过两家子公司开展业务:Renovaro Biosciences(负责细胞和基因治疗项目)以及 BioSymetrics(于2025年4月8日收购,提供用于生物标志物发现和疗法开发的人工智能与机器学习平台,涵盖癌症诊断、中枢神经系统疾病和生物防御等多个领域)。第三家全资子公司Lunai Bioworks IP, Inc.持有源自 2026 年 5 月收购Neurobridge交易的知识产权,其中包括N2B鼻内药物递送平台。尽管GEDi Cube B.V.在截至2025年9月30日的季度内经历了破产及合并报表范围剔除,但公司的战略方向保持不变;BioSymetrics拥有的互补性能力确保了公司人工智能驱动的生物医学研发战略得以延续并拓展。目前的合并业务涵盖Renovaro Biosciences的细胞与基因治疗项目以及BioSymetrics的人工智能驱动生物技术平台,通过结合多模态数据分析与实验生物学,旨在加速研发进程,并提升疗法及化学防御制剂发现的效率。","exchange":"PINK","name":"Lunai Bioworks","nameEN":"Lunai Bioworks"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lunai Bioworks(LNAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lunai Bioworks(LNAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lunai Bioworks,LNAI,Lunai Bioworks股票,Lunai Bioworks股票老虎,Lunai Bioworks股票老虎国际,Lunai Bioworks行情,Lunai Bioworks股票行情,Lunai Bioworks股价,Lunai Bioworks股市,Lunai Bioworks股票价格,Lunai Bioworks股票交易,Lunai Bioworks股票购买,Lunai Bioworks股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lunai Bioworks(LNAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lunai Bioworks(LNAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}